Clinical datasets from England for high-risk prostate cancer patients were used to compare the effects of radiotherapy added to hormone therapy (RT+HT) and hormone therapy only (HT) on all-cause mortality.
doi.org/10.1016/j.jclinepi....
“Results
A total of 2,690 patients were eligible for inclusion in the emulated trial. The CCW analysis using a grace period of 6 months gave an estimated HR of 0.48 (95%CI: 0.34-0.60) and 7-year survival estimates of 80.7% (95%CI: 74.3-87.0) for the RT+HT strategy and 65.6% (95%CI: 62.8, 68.1) for HT only strategy, and corresponding risk difference of 15.1% (95%CI: 11.5-18.9). The corresponding HR from the landmark-CCW approach was 0.58 (95%CI: 0.51-0.65) and with survival estimates of 80.7% (95%CI: 77.7-83.8) for RT+HT strategy and 69.8% (95%CI: 68.2-71.4) for the HT only strategy, and a risk difference of 10.9% (95%CI: 6.3-15.9).”